Abstract

Lymphoma in Patients with Inflammatory Bowel Disease: A Multicentre Collaborative Study Between GETAID and LYSA

J Crohns Colitis. 2024 Apr 23;18(4):533-539.doi: 10.1093/ecco-jcc/jjad177.

 

Marie Muller 1Julien Broséus 2 3Adrien Guilloteau 4Stéphane Wasse 4Catherine Thiéblemont 5Stéphane Nancey 6Guillaume Cadiot 7Aurélien Amiot 8David Laharie 9Sophie Vieujean 10Yoram Bouhnik 11Chloé Martineau 12Christophe Michiels 13Xavier Hebuterne 14Guillaume Savoye 15Denis Franchimont 16Philippe Seksik 17Laurent Beaugerie 17Marc Maynadié 4Pierre Feugier 2 18Laurent Peyrin-Biroulet 1 2

 
     

Author information

1Department of Gastroenterology, Nancy University Hospital, University of Lorraine, Nancy, France.

2University of Lorraine, Inserm U1256 « Nutrition - Genetics and exposure to environmental risks - NGERE », F-54000, Nancy, France.

3University of Lorraine, CHRU-Nancy Hematology Laboratory, Laboratory Department, F-54000 Nancy, France.

4Registre des hemopathies Malignes de Côte d'Or, Inserm U1231, University of Burgundy and Dijon University Hospital, Dijon, France.

5AP-HP, Saint-Louis Hospital, Hemato-oncology, University of Paris, Paris, France.

6Department of Gastroenterology, University Claude Bernard Lyon 1, Hospices Civils de Lyon, CHU Lyon-Sud, Lyon, France.

7Department of Hepato-Gastro-Enterology, Reims University Hospital, Reims, France.

8Department of Gastroenterology, Henri Mondor University Hospital, AP-HP, Paris Est Créteil University, Créteil, France.

9Department of Hepato-Gastro-Enterology, Bordeaux University Hospital, Pessac, France.

10Department of Hepato-Gastroenterology, University Hospital CHU of Liège, Liège, Belgium.

11Institut National de la Santé et Recherche Médicale et Université Paris Diderot, Paris Hôpital Beaujon, AP-HP, Paris, France.

12Department of Gastroenterology, Hôpital Européen George Pompidou, AP-HP, Paris, France.

13Department of Hepato-Gastro-Enterology, Dijon University Hospital, Dijon, France.

14Department of Hepato-Gastro-Enterology, Nice University Hospital, Nice, France.

15Department of Hepato-Gastro-Enterology, Rouen University Hospital, Rouen, France.

16Department of Hepato-Gastro-Enterology, Erasme University Hospital, Brussels, Belgium.

17Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Saint-Antoine, Department of Gastroenterology, F75012, Paris, France.

18Department of Clinical Hematology, Nancy University Hospital, University of Lorraine, Nancy, France.

Abstract

Background: Inflammatory bowel disease [IBD] is associated with an increased risk of developing lymphoma. Although recent data have clarified the epidemiology of lymphoma in IBD patients, the clinical and pathological characteristics of lymphoma in IBD remain poorly known.

Methods: Patients with IBD and lymphoma were retrospectively identified in the framework of a national collaborative study including the Groupe d'Étude Thérapeutique des Affections Inflammatoires du Tube Digestif [GETAID] and the Lymphoma Study Association [LYSA]. We characterized clinical and prognostic features for the three most frequent lymphoma subtypes occurring in IBD. We performed a multicentre case-control study. Controls [lymphoma de novo] were matched [5:1] to cases on gender, age at diagnosis, lymphoma subtype, year of diagnosis, and IPI/FLIPI indexes. Overall survival and progression-free survival were compared between cases and controls.

Results: In total, 133 IBD patients with lymphoma were included [males = 62.4%, median age at lymphoma diagnosis = 49 years in males; 42 years in females]. Most had Crohn's disease [73.7%] and were exposed to thiopurines [59.4%]. The most frequent lymphoma subtypes were diffuse large B cell lymphoma [DLBCL, 45.1%], Hodgkin lymphoma [HL, 18.8%], and follicular lymphoma [FL, 10.5%]. When matched with 365 controls, prognosis was improved in IBD patients with DLBCL compared to controls [p = 0.0064, hazard ratio = 0.36] or similar [HL and FL].

Conclusions: Lymphomas occurring in IBD patients do not seem to have a worse outcome than in patients without IBD. Due to the rarity of this situation, such patients should be managed in expert centres.

© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.